BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period

San Francisco-based Olema Oncology secured $54 million in an oversubscribed Series B financing round to support the development of the company’s lead breast cancer treatment as well as expand ongoing research and development programs.

Morphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.